Top Purchase Related
Home
>
Node
>
Subnode

Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy

MMW Fortschritte der Medizin 142(3 Suppl): 41

2000

ISSN/ISBN: 1438-3276
PMID: 11012293
Document Number: 525651

Document emailed within 1 workday
Secure & encrypted payments

Chong, K.T.; Pagano, P.J. 1997: In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates Antimicrobial Agents and ChemoTherapy 41(11): 2367-2373
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Hammer, S.M.; Vaida, F.; Bennett, K.K.; Holohan, M.K.; Sheiner, L.; Eron, J.J.; Wheat, L.Joseph.; Mitsuyasu, R.T.; Gulick, R.M.; Valentine, F.T.; Aberg, J.A.; Rogers, M.D.; Karol, C.N.; Saah, A.J.; Lewis, R.H.; Bessen, L.J.; Brosgart, C.; DeGruttola, V.; Mellors, J.W. 2002: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial JAMA 288(2): 169-180
Marcelin, A.-G.; Flandre, P.; de Mendoza, C.; Roquebert, B.; Peytavin, G.; Valer, L.; Wirden, M.; Abbas, S.; Katlama, C.; Soriano, V.; Calvez, V. 2007: Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients Antiviral Therapy 12(2): 247-252
Kuschak, D.; Mauss, S.; Schmutz, G.; Gantke, B. 2001: Simultaneous Determination of the New HIV Protease Inhibitor Lopinavir (ABT 378) and of Indinavir (1), Amprenavir, Saquinavir, Ritonavir (ABT 538) (2) and Nelfinavir (3) in Human Plasma by Gradient HPLC Clinical Laboratory 47(9-10): 471-477
Manosuthi, W.; Sungkanuparph, S.; Ruxrungtham, K.; Prasithsirikul, W.; Athichathanabadi, C.; Tantisiriwat, W.; Bowonwatanuwong, C.; Chumpathat, N.; Chaovavanich, A. 2008: Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir Journal of Acquired Immune Deficiency Syndromes 47(1): 127-129
Gianotti, N.; Poli, A.; Galli, M.; Pan, A.; Rizzardini, G.; Soria, A.; Viale, P.; Di Biagio, A.; Quirino, T.; Viganò, P.; Bonfanti, P.; d'Arminio Monforte, A.; Fortino, I.; Lazzarin, A. 2014: Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study New Microbiologica 37(4): 439-448
Piketty, C.; Gérard, L.; Chazallon, C.; Marcelin, A.-G.èv.; Clavel, F.ço.; Taburet, A.-M.; Calvez, V.; Madelaine-Chambrin, I.; Molina, J.-M.; Aboulker, J.-P.; Girard, P.-M. 2006: Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial Antiviral Therapy 11(2): 213-221
Gutiérrez, Félix.; Padilla, S.; Masiá, M.; Navarro, Aés.; Gallego, J.; Hernández, I.; Ramos, Jé.Manuel.; Martin-Hidalgo, A. 2004: Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations Antiviral Therapy 9(1): 105-113
Lalezari, J.P.; DeJesus, E.; Northfelt, D.W.; Richmond, G.; Wolfe, P.; Haubrich, R.; Henry, D.; Powderly, W.; Becker, S.; Thompson, M.; Valentine, F.; Wright, D.; Carlson, M.; Riddler, S.; Haas, F.F.; DeMasi, R.; Sista, P.R.; Salgo, M.; Delehanty, J. 2003: A controlled Phase Ii trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults Antiviral Therapy 8(4): 279-287
Koudriakova, T.; Iatsimirskaia, E.; Utkin, I.; Gangl, E.; Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N. 1998: Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir Drug Metabolism and Disposition: the Biological Fate of Chemicals 26(6): 552-561
Toyo-oka, T.; Kamishiro, T.; Gotoh, Y.; Fumino, H.; Masaki, T.; Hosoda, S. 1986: Temporary salvage of ischemic myocardium by the protease inhibitor bis[ethyl(2R,3R)-3-[(S)-methyl-1-[4-(2,3,4-trimethoxyphenyl-methyl) piperazin-1-ylcarbonyl]butyl-carbonyl]oxiran-2-carbo xylate]sulfate Arzneimittel-Forschung 36(4): 671-675
Cameron, D.W.; Japour, A.J.; Xu, Y.; Hsu, A.; Mellors, J.; Farthing, C.; Cohen, C.; Poretz, D.; Markowitz, M.; Follansbee, S.; Angel, J.B.; McMahon, D.; Ho, D.; Devanarayan, V.; Rode, R.; Salgo, M.; Kempf, D.J.; Granneman, R.; Leonard, J.M.; Sun, E. 1999: Ritonavir and saquinavir combination therapy for the treatment of HIV infection Aids 13(2): 213-224
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Besson, C.; Jubault, V.; Viard, J.P.; Pialoux, G. 1998: Ketoacidosis associated with protease inhibitor therapy Aids 12(11): 1399-1400
Cabot de Vega, E.; Fontecha Gómez, B.J.; Solé Arnau, R.; Pedrol Clotet, E. 1999: Peripheral lipodystrophy associated with protease inhibitor therapy Revista Clinica Espanola 199(8): 546-547
Sangraula, H.; Sharma, K.K.; Dwivedi, S. 2001: Antiretroviral protease inhibitor therapy leads to hyperglycaemia, hyperlipidaemia and lipodystrophy National Medical Journal of India 14(6): 347-348
Patel, A.K.; Patel, K.K.; Naik, E.; Jingyi Duan; Ranjan, R.; Patel, J.K.; Salihu, H.M. 2011: Comparison of the Effectiveness of Low-Dose Indinavir/Ritonavir (IDV/r)- versus Atazanavir/Ritonavir (ATV/r)-Based Generic Antiretroviral Therapy in NNRTI-Experienced HIV-1-Infected Patients in India Journal of the International Association of Physicians in Aids Care 10(2): 111-118
2000: Holding option open for subsequent treatment. Beginning therapy with a protease inhibitor MMW Fortschritte der Medizin 142(3 Suppl): 8-9